142 related articles for article (PubMed ID: 17001259)
1. Clinical and economic outcomes of nonadherence to highly active antiretroviral therapy in patients with human immunodeficiency virus.
Munakata J; Benner JS; Becker S; Dezii CM; Hazard EH; Tierce JC
Med Care; 2006 Oct; 44(10):893-9. PubMed ID: 17001259
[TBL] [Abstract][Full Text] [Related]
2. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection.
Goldie SJ; Paltiel AD; Weinstein MC; Losina E; Seage GR; Kimmel AD; Walensky RP; Sax PE; Freedberg KA
Am J Med; 2003 Dec; 115(8):632-41. PubMed ID: 14656616
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
Brogan AJ; Talbird SE; Cohen C
Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
[TBL] [Abstract][Full Text] [Related]
4. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.
Sanders GD; Bayoumi AM; Sundaram V; Bilir SP; Neukermans CP; Rydzak CE; Douglass LR; Lazzeroni LC; Holodniy M; Owens DK
N Engl J Med; 2005 Feb; 352(6):570-85. PubMed ID: 15703422
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of counseling strategies to improve adherence to highly active antiretroviral therapy among men who have sex with men.
Zaric GS; Bayoumi AM; Brandeau ML; Owens DK
Med Decis Making; 2008; 28(3):359-76. PubMed ID: 18349433
[TBL] [Abstract][Full Text] [Related]
7. Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective.
Marcellusi A; Viti R; Russo S; Andreoni M; Antinori A; Mennini FS
Clin Drug Investig; 2016 May; 36(5):377-87. PubMed ID: 26940802
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis.
Bendavid E; Grant P; Talbot A; Owens DK; Zolopa A
AIDS; 2011 Jan; 25(2):211-20. PubMed ID: 21124202
[TBL] [Abstract][Full Text] [Related]
9. Expanded screening for HIV in the United States--an analysis of cost-effectiveness.
Paltiel AD; Weinstein MC; Kimmel AD; Seage GR; Losina E; Zhang H; Freedberg KA; Walensky RP
N Engl J Med; 2005 Feb; 352(6):586-95. PubMed ID: 15703423
[TBL] [Abstract][Full Text] [Related]
10. The cost effectiveness of combination antiretroviral therapy for HIV disease.
Freedberg KA; Losina E; Weinstein MC; Paltiel AD; Cohen CJ; Seage GR; Craven DE; Zhang H; Kimmel AD; Goldie SJ
N Engl J Med; 2001 Mar; 344(11):824-31. PubMed ID: 11248160
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease.
Sax PE; Losina E; Weinstein MC; Paltiel AD; Goldie SJ; Muccio TM; Kimmel AD; Zhang H; Freedberg KA; Walensky RP
J Acquir Immune Defic Syndr; 2005 May; 39(1):69-77. PubMed ID: 15851916
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
Simpson KN; Luo MP; Chumney EC; King MS; Brun S
Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
Broder MS; Chang EY; Bentley TG; Juday T; Uy J
J Med Econ; 2011; 14(2):167-78. PubMed ID: 21288058
[TBL] [Abstract][Full Text] [Related]
14. Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness.
Weinstein MC; Goldie SJ; Losina E; Cohen CJ; Baxter JD; Zhang H; Kimmel AD; Freedberg KA
Ann Intern Med; 2001 Mar; 134(6):440-50. PubMed ID: 11255519
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of preventing AIDS-related opportunistic infections.
Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
[TBL] [Abstract][Full Text] [Related]
16. The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda.
Marseille E; Kahn JG; Pitter C; Bunnell R; Epalatai W; Jawe E; Were W; Mermin J
Appl Health Econ Health Policy; 2009; 7(4):229-43. PubMed ID: 19905037
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.
Sendi P; Günthard HF; Simcock M; Ledergerber B; Schüpbach J; Battegay M;
PLoS One; 2007 Jan; 2(1):e173. PubMed ID: 17245449
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
[TBL] [Abstract][Full Text] [Related]
19. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of 'test and treat' policy for antiretroviral therapy among heterosexual HIV population in India.
Singh M; Sharma A; Bahuguna P; Jyani G; Prinja S
Indian J Med Res; 2022 Jun; 156(6):705-714. PubMed ID: 37056069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
